Please assess the completion status of the following clinical trial:

Trial Title: Anticoagulation Length in Cancer Associated Thrombosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Receiving LMWH for treatment of CAT for five months~* Locally advanced or metastatic cancer~* Able to self-administer LMWH, or have LMWH administered by a carer~* Able to give informed consent~* Age ≥16 years~Exclusion Criteria:~* Receiving drug other than LMWH for CAT~* Contraindication to anticoagulation~* Fitted with a prosthetic heart valve~* Pregnant and/or lactating females

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A: Continue treatment (Type: EXPERIMENTAL): Continue low molecular weight heparin (LMWH) at treatment dose according to body weight for further six months.
- B: Discontinue treatment (Type: NO_INTERVENTION): Discontinue low molecular weight heparin (LMWH) once patient has received six months treatment following index VTE case.

Based on this trial design, predict the completion outcome and termination type (if applicable).